Christopher Ohms

1 month ago | cellandgene.com | Christopher Ohms |Tyler Menichiello |Cal Collins

Webinar: Critical Imaging Risks in GLP-1 and Neurology Studies: What You Need to KnowClinical trials in GLP-1 and neurology rely increasingly on imaging, but challenges often go unaddressed. This webinar covers early indicators of imaging issues, preclinical insights, expanding imaging requirements, and hidden risks.

Dec 2, 2024 | pharmaceuticalonline.com | Christopher Ohms

By Christopher Ohms, Ohms Consulting Predicting specific advancements in the pharmaceutical supply chain over the next decade involves a degree of speculation, yet several trends and potential developments can be anticipated based on current technological trajectories. Maintaining the optimal health of the pharmaceutical supply chain — focused on efficiency, reliability, and resiliency — will be critical.

Nov 15, 2024 | outsourcedpharma.com | Christopher Ohms |Louis Garguilo

By Christopher Ohms, Ohms Consulting For decades, the U.S. pharmaceutical industry has relied heavily on China and India to produce regulatory starting materials (RSMs) and active pharmaceutical ingredients (APIs). These two countries offer substantial economic advantages, established supply chains, and skilled workforces, making them dominant suppliers in the global pharmaceutical market.

Nov 12, 2024 | bioprocessonline.com | Christopher Ohms

Guest Column | November 12, 2024 By Christopher Ohms, Ohms Consulting Transitioning from clinical-stage operations to commercial readiness in the pharmaceutical industry is a complex, multifaceted process that requires accurate planning, execution, and ongoing monitoring. It demands careful attention to both operational and regulatory details to ensure a successful product launch.

Apr 10, 2024 | clinicalleader.com | Christopher Ohms |Dan Schell

Understanding The Key Differences Between EAPs And ISTsExpanded Access Programs (EAPs) and Investigator-Sponsored Trials (ISTs) are pivotal, granting access to investigational therapies. Recognizing their distinctions from traditional trials is crucial for investigational medicine and supply chains, ensuring efficient operations.